Abstract
Introduction
Transoral incisionless fundoplication (TIF) with the EsophyX™ device is reported to be effective for creating a continent gastroesophageal valve and for good functional results, as measured by pH impedance in patients with gastroesophageal reflux disease (GERD). The aim of this study is to assess the long-term effect of TIF in patients with symptomatic GERD.
Patients and methods
TIF 2.0 fundoplication was done in 42 consecutive patients. All were studied with GERD-HRQL and GERD-QUAL questionnaires, upper gastrointestinal (GI) endoscopy, esophageal manometry, and 24 h pH impedance before and at 6, 12, and 24 months after TIF.
Results
In all, 35 patients completed 6-month follow-up; 21 (60.0%) completely stopped proton pump inhibitor (PPI) therapy, 6 (17.1%) more than halved it, and 8 (22.9%) continued with the same dose as before the procedure. There were 26 patients with complete 24-month follow-up; 11 (42.3%) completely stopped PPI therapy, 7 (26.9%) more than halved it, and 8 (30.8%) were taking the same dose as before the procedure. Hiatal hernia and ineffective esophageal motility seemed to raise the risk of recurrence of symptoms (p = 0.02 and p < 0.001, respectively). The number of fasteners deployed during TIF was the only factor predictive of successful outcome (p = 0.018).
Conclusions
TIF using the EsophyX device allowed withdrawal or reduction of PPI in about 77% of patients at 6-month follow-up and about 69% at 24 months. Larger number of fasteners deployed during TIF was predictive of positive outcome; pre-TIF ineffective esophageal motility and hiatal hernia raised the risk of recurrence of GERD symptoms, but were not significant from a prospective point of view.
Abbreviations
- GER:
-
Gastroesophageal reflux
- GERD:
-
Gastroesophageal reflux disease
- LES:
-
Lower esophageal sphincter
- PPI:
-
Proton pump inhibitors
- TIF:
-
Transoral incisionless fundoplication
- DEA:
-
Distal esophageal amplitude
- SAP:
-
Symptom association probability
- BMI:
-
Body mass index
- IEM:
-
Ineffective esophageal motility
References
Cadière GB, Rajan A, Rquibate M, Germay O, Dapri G, Himpens J, Gawlicka AK (2006) Endoluminal Fundoplication (ELF)–evolution of EsophyX™, a new surgical device for transoral surgery. Minim Invasive Ther Allied Technol 15:348–355
Bell RC, Cadière GB (2010) Transoral rotational esophagogastric fundoplication: technical, anatomical, and safety considerations. Surg Endosc. doi:10.1007/s00464-010-1528-6
Cadiere GB, Rajan A, Germay O, Himpens J (2008) Endoluminal fundoplication by a transoral device for the treatment of GERD: a feasibility study. Surg Endosc 22:333–342
Cadiere GB, Buset M, Muls V, Rajan A, Rösch T, Eckardt AJ, Weerts J, Bastens B, Costamagna G, Marchese M, Louis H, Mana F, Sermon F, Gawlicka AK, Daniel MA, Devière J (2008) Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg 32:1676–1688
Cadiere GB, Van Sante N, Graves JE, Gawlicka AK, Rajan A (2009) Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using Esophyx. Surg Endosc 23:957–964
Testoni PA, Corsetti M, Di Pietro S, Castellaneta AG, Vailati C, Masci E, Passaretti S (2010) Effect of transoral incisionless fundoplication on symptoms, PPI use, and pH-impedance refluxes of GERD patients. World J Surg 34(4):750–757
Demyttenaere SV, Bergman S, Pham T, Anderson J, Dettorre R, Melvin WS, Mikami DJ (2010) Transoral incisionless fundoplication for gastro-esophageal reflux disease in an unselected patient population. Surg Endosc 24:854–858
Repici A, Fumagalli U, Malesci A, Barbera R, Gambaro C, Rosati R (2010) Endoluminal fundoplication (ELF) for GERD using Esophyx: a 12-month follow-up in a single-center experience. J Gastrointest Surg 14:1–6
Bell RC, Freeman KD (2010) Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease. Surg Endosc. doi:10.1007/s00464-010-1497-9
Triadafilopoulos G (2007) Endotherapy and Surgery for GERD. J Clin Gastroenterol 41(Suppl 2):S87–S96
Portale G, Filipi CJ, Peters JH (2004) A current assessment of endoluminal approaches to the treatment of gastroesophageal reflux disease. Surg Innov 4:225–234
Fry LC, Monkenmuller K, Malfertheiner P (2007) Systematic review: endoluminal therapy for gastro-oesophageal reflux disease: evidence from clinical trials. Eur J Gastroenterol Hepatol 19: 1125–1139
Drossman DA (2006) The functional gastrointestinal disorders and the Rome III process. Gastroenterology 130:1377–1390
Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L (1999) Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles Classification. Gut 45:172–180
Velanovich V, Vallance SR, Gusz JR, Tapia FV, Harkabus MA (1996) Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg 183:217–224
Raymond JM, Marquis P, Bechade D, Smith D, Mathiex Fortunet H, Poynard T, Galmiche JP, Amouretti M (1999) Assessment of quality of life of patients with gastroesophageal reflux. Elaboration and validation of a specific questionnaire. Gastroenterol Clin Biol 23:32–39
Jobe BA, Kahrilas PJ, Vernon AH, Sandone C, Gopal DV, Swanstrom LL, Aye RW, Hill LD, Hunter JG (2004) Endoscopic appraisal of the gastroesophageal valve after antireflux surgery. Am J Gastroenterol 99:233–243
Jobe BA, O’Rourke RW, McMahon BP, Gravesen F, Lorenzo C, Hunter JG, Bronner M, Kraemer SJ (2008) Transoral endoscopic fundoplication in the treatment of gastroesophageal reflux disease. The anatomic and physiologic basis for reconstruction of the esophago-gastric junction using a novel device. Ann Surg 248:69–76
Hill D, Kozarek RA (1999) The gastroesophageal flap valve. J Clin Gastroenterol 28:194–197
Malmud LS, Fischer RS, Knight LC, Rock E (1982) Scintigraphic evaluation of gastric emptying. Semin Nucl Ned 12:116–125
Passaretti S, Zaninotto G, Di Martino N, Leo P, Costantini M, Baldi F (2000) Standards for esophageal manometry. A position statement of GISMAD. Dig Liver Dis 32:46–55
Spechler SJ, Castell DO (2001) Classification of oesophageal motility abnormalities. Gut 49:145–151
Zerbib F, des Varannes SB, Roman S, Pouderoux P, Artigue F, Chaput U, Mion F, Caillol F, Verin E, Bommelaer G, Ducrotté P, Galmiche JP, Sifrim D (2005) Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther 22:1011–1021
Johnson LF, DeMeester TR (1986) Development of the 24-hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol 8:52–58
Zagol B, Mikami D (2011) Advances in transoral fundoplication for oesophageal reflux. Dig Liver Dis. doi:10.1016/j.dld.2011.01.006
Lundell L, Miettinen P (2001) Continued (5 years) follow up of a randomized clinical study comparing antireflux surgery and omeprazole in GERD. J Am Col Surg 192:171–182
Draaisma WE, Rijnhart-de Jong HG, Broeders IAMJ, Smout AJ, Furnee EJ, Gooszen HG (2006) Five-year subjective and objective results of laparoscopic and conventional Nissen fundoplication. Ann Surg 244:34–41
Smith CD (2009) Surgical therapy for gastroesophageal reflux disease: indications, evaluation and procedures. Gastrointest Endoscopy Clin North Am 19:35–48
Broeders JA, Draaisma WA, Bredenoord AJ, Smout AJ, Broeders IA, Gooszen HG (2010) Long-term outcome of Nissen fundoplication in non-erosive and erosive gastro-esophageal reflux disease. Br J Surg 97:845–852
Velanovich V (2010) Endoscopic, endoluminal fundoplication for gastroesophageal reflux disease: initial experience and lessons learned. Surgery. doi:10.1016/j.surg.2010.07.031
Barnes WE, Hoddinott KM, Mundy S, Williams M (2011) Transoral incisionless fundoplication offers high patient satisfaction and relief of therapy-resistant typical and atypical symptoms of GERD in community practice. Surg Innov. doi:10.1177/1553350610392067
Hoppo T, Immanuel A, Schuchert M, Dubrava Z, Smith A, Nottle P, Watson DI, Jobe BA (2010) Transoral incisionless fundoplication 2.0 procedure using EsophyX™ for gastroesophageal reflux disease. J Gastrointest Surg. doi:10.1007/s11605-010-1331-7
Richter JE (2007) The many manifestations of gastro-esophageal reflux disease: presentation, evaluation, and treatment. Gastroenterol Clin North Am 36:577–599
Kim KY, Kim GH, Kim DU, Wang SG, Lee BJ, Lee JC, Park DY, Song GA (2008) Is ineffective esophageal motility associated with gastropharyngeal reflux disease? World J Gastroenterol 14:6030–6035
Haack HG, Hansen RD, Malcolm A, Kellow JE (2008) Ineffective oesophageal motility: manometric subsets exhibit different symptom profiles. World J Gastroenterol 14:3719–3724
Disclosures
Author Cristian Vailati’s data presentation at DDW 2010 was supported by the manufacturer of the device. Authors Pier Alberto Testoni, Sabrina Testoni, and Maura Corsetti have no conflicts of interest or financial ties to disclose.
Financial support
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Testoni, P.A., Vailati, C., Testoni, S. et al. Transoral incisionless fundoplication (TIF 2.0) with EsophyX for gastroesophageal reflux disease: long-term results and findings affecting outcome. Surg Endosc 26, 1425–1435 (2012). https://doi.org/10.1007/s00464-011-2050-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-011-2050-1